This week, catching up with Medtronic’s Senior Director of Global Medical Affairs Dr. Jennifer McVean. It’s been one year since the 780G was approved in the US, what does the device – and its seven-day infusion set – look like in the real world. Plus, we have a big discussion about the future of type 1 diabetes – Dr. McVean has lead some significant trials – she lives with type 1 and has some big ideas about changes she’d like to see.
This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Find out more about Moms' Night Out
Please visit our Sponsors & Partners - they help make the show possible!
Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)
Check out VIVI Cap to protect your insulin from extreme temperatures
Learn more about AG1 from Athletic Greens
Drive research that matters through the T1D Exchange
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: info@diabetes-connections.com
This week, the newest pump coming to the market is called the twiist. It’s a very different shape – circular with a top half that twists off – with very different software – Tidepool Loop. The company behind this pump – they’re called Sequel - wants to be different as well, hoping to offer solutions to bigger issue than basal and bolus rates. It’s very ambitious and we have a wide ranging conversation about it all with Sequel’s CEO Alan Lotvin
This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Our episode about Tidepool Loop approval
Find out more about Moms' Night Out
Please visit our Sponsors & Partners - they help make the show possible!
Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)
Check out VIVI Cap to protect your insulin from extreme temperatures
Learn more about AG1 from Athletic Greens
Drive research that matters through the T1D Exchange
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: info@diabetes-connections.com
It’s In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: Dexcom launches direct-to-watch with the G7 in the UK and Ireland, more studies looking at heart benefits with Wegovy and diabetes, a new T1D study investigating an injectable to prevent overnight hypoglycemia, lobbying for Levimir, a ChatGPT diabetes diagnosis and more!
Find out more about Moms' Night Out
Please visit our Sponsors & Partners - they help make the show possible!
Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)
Check out VIVI Cap to protect your insulin from extreme temperatures
Learn more about AG1 from Athletic Greens
Drive research that matters through the T1D Exchange
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: info@diabetes-connections.com
There used to be a lot of bolus calculators in the app store, maybe you’ve used one and haven’t updated it in a while. Don’t try now.. it’s likely been pulled. Apple and the FDA are cracking down on this types of tools – no unreasonable, right? But surely there are more coming.. how hard can it be to create a simple insulin bolus calculator that’s FDA approved, easy to find, easy to use, free, and doesn’t require you buy anything else? Turns out, it’s pretty darn hard. We’re talking about that today with the inventor of such an app with an interesting story – he’s still in high school.
My guest this week was diagnosed with type 1 at age 13 – and while he and his family were calling in every blood sugar to help their doctor make adjustments, he thought there should be a better way. So Drew Mendelow created T1D1. I’ll let him and his parents Laura and Mike tell you more about it and what makes it unique.
It was recommended by his doctors to other patients and the word spread – they had tens of thousands of downloads. But in 2021, the FDA started cracking down on these kinds of apps and Apple pulled it. Drew has been working toward approval ever since and they’re pretty close.
This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Find out more about Moms' Night Out
Please visit our Sponsors & Partners - they help make the show possible!
Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)
Check out VIVI Cap to protect your insulin from extreme temperatures
Learn more about AG1 from Athletic Greens
Drive research that matters through the T1D Exchange
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: info@diabetes-connections.com
Diabetes technology is getting better and better. We have automated insulin systems that link pumps and CGMs, and smart insulin pens that have precise calculations and reminders. It’s been quite the evolution over the past few years! But outcomes – time in range, A1Cs, aren’t exactly where experts thought they might be. I’m talking to Dr. Stephen Ponder about why that is, how a social media post he shared about this caused a strong reaction, and what does work for better long term outcomes.
This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Find out more about Moms' Night Out
Please visit our Sponsors & Partners - they help make the show possible!
Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)
Check out VIVI Cap to protect your insulin from extreme temperatures
Learn more about AG1 from Athletic Greens
Drive research that matters through the T1D Exchange
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: info@diabetes-connections.com
It's In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: a new study shows that drugs like Ozempic can be produced for just a few dollars, we upate the insulin vial shortage Lilly announced, a new pump has been FDA cleared, a genetically modified cow can product human insulin, and more!
Transcript and links below
Find out more about Moms' Night Out
Please visit our Sponsors & Partners - they help make the show possible!
Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)
Check out VIVI Cap to protect your insulin from extreme temperatures
Learn more about AG1 from Athletic Greens
Drive research that matters through the T1D Exchange
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: info@diabetes-connections.com
Approved last year, Tandem’s Mobi is now widely available. We’re getting an update from Ben Mar, Director of Product Marketing, on the features of the Mobi that make this tiny pump different and we look ahead to what Tandem is working on next. Ben also answers your questions about everything from algorithm updates, international access, and much more
This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Find out more about Moms' Night Out
Please visit our Sponsors & Partners - they help make the show possible!
Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)
Check out VIVI Cap to protect your insulin from extreme temperatures
Learn more about AG1 from Athletic Greens
Drive research that matters through the T1D Exchange
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
This week, one of the pioneers of the DIY movement is turning her attention to exercise. Dana Lewis is partnering with other researchers to create a tool to help you make better and easier decisions around whatever workout you choose. There’s a lot of variability here – big difference between say, weight lifting and long distance running – so this is no easy task. Dana will explain the tools they’re using, the big goals here, and we get to catch up about what she’s using these days to manage her life with T1D which now includes ultramarathoning.
This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Here's more about the Helmsley grants Stacey mentioned
Here's more about T1Dexi
Here are our previous episodes with Dana
Find out more about Moms' Night Out
Please visit our Sponsors & Partners - they help make the show possible!
Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)
Check out VIVI Cap to protect your insulin from extreme temperatures
Learn more about AG1 from Athletic Greens
Drive research that matters through the T1D Exchange
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: info@diabetes-connections.com
It's In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: The annual ATTD conference wraps up with news about CGMs, including new FDA approvals and a look at CGMs outside of the US, new eyedrops are being studied to treat diabetic eye disease and Beyond Type 1 opens applications for their annual Beyond Scholars.
Transcript and links below
Find out more about Moms' Night Out
Please visit our Sponsors & Partners - they help make the show possible!
Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)
Check out VIVI Cap to protect your insulin from extreme temperatures
Learn more about AG1 from Athletic Greens
Drive research that matters through the T1D Exchange
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: info@diabetes-connections.com
Let's talk about driving with diabetes! Getting a driver’s license as a teenager comes with enough challenges without type 1, but letting your child with T1D get behind the wheel is stressful, to say the least! I’m sharing what worked for us and expert advice that may help you and tips to let technology be your friend in the car.
This is an excerpt of Stacey's book, "Still the World's Worst Diabetes Mom." It's the second book in her series. You can learn more about the books here on Amazon or on our website.
Learn more about Moira McCarthy's book that Stacey mentions here.
This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Find out more about Moms' Night Out
Please visit our Sponsors & Partners - they help make the show possible!
Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)
Check out VIVI Cap to protect your insulin from extreme temperatures
Learn more about AG1 from Athletic Greens
Drive research that matters through the T1D Exchange
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: info@diabetes-connections.com
This week, addressing something that half of all people with diabetes experience but that there is woefully little information and study about. Why is there so little study about periods and type 1 diabetes? We’re talking to two organizations who are teaming up to change that – but they need your help. We’re talking about Tidepool's Period Project.
This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
You'll hear from Martina Rothenbühler, project leader data sciences and data protection officer at DCB, and Maya Friedman, founder of The Period Project at Tidepool.
Learn more and sign up for the study here: Menstrual Cycle Study: Identifying changes in insulin sensitivity across the menstrual cycle in T1D - Diabetes Center Berne (dcberne.com)
Find out more about Moms' Night Out
Please visit our Sponsors & Partners - they help make the show possible!
Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)
Check out VIVI Cap to protect your insulin from extreme temperatures
Learn more about AG1 from Athletic Greens
Drive research that matters through the T1D Exchange
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: info@diabetes-connections.com
It’s In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: what is MicroGlucagon and how could it speed up existing rapid-acting insulin? SGLT2 medications may cause false positive alcohol tests, red light therapy for type 2 diabetes, research shows teens with type 2 might have a different kind of diabetes altogether, FDA warns against non-invasive glucose monitoring and more!
Find out more about Moms' Night Out
Please visit our Sponsors & Partners - they help make the show possible!
Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)
Check out VIVI Cap to protect your insulin from extreme temperatures
Learn more about AG1 from Athletic Greens
Drive research that matters through the T1D Exchange
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: info@diabetes-connections.com
She calls it the Chaos Lottery – and says we all have different ways of dealing with what life throws our way. I’m talking to Sarah Stewart Holland, host of the huge podcast Pantsuit Politics about her family’s journey with diabetes – her young son was diagnosed almost two years ago. She has a lot to say about parenting a child with a chronic condition – this is not her son’s first serious diagnosis – and also about roles and identity and being a person without type 1 whos’ raising a person with type 1. It’s a lot and it’s great.
This interview was taped at Moms' Night Out Charlotte. I think it's a great example of what happens at these events. We moms aren't looking for perfection, we're looking for community.
This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Find out more about Moms' Night Out
Here's the episode of Pantsuit Politics with Stacey
Please visit our Sponsors & Partners - they help make the show possible!
Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)
Check out VIVI Cap to protect your insulin from extreme temperatures
Learn more about AG1 from Athletic Greens
Drive research that matters through the T1D Exchange
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: info@diabetes-connections.com
We are far away from New Year’s resolutions and it’s feeling a little wintry and dreary around here. Good time to get some motivation and check in with Chris Ruden. Many of you know likely know Chris – who lives with type 1 - from his appearance on the Titan games, his bodybuilding videos or maybe it’s the videos where he shows his prosthetic hand.
Chris has a lot to say about where all of that has brought him and what’s different for him now. He also uses the implantable Eversense CGM – always a lot of questions about that, so I asked him all about it.
More about Friends for Life here
This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Find out more about Moms' Night Out
Please visit our Sponsors & Partners - they help make the show possible!
Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)
Check out VIVI Cap to protect your insulin from extreme temperatures
Learn more about AG1 from Athletic Greens
Drive research that matters through the T1D Exchange
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: info@diabetes-connections.com
It’s In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: Tandem announces it's taking orders and starting to ship the Mobi pump, Insulet gets European approval for the Abbott Libre integration with Omnipod 5, new study looks at type 2 remission and gastric bypass surgery, one type of medication seems to do a much better job preventing kidney stones in people with type 2, big new grant to look at exercise and type 1 and a look back at diabetes at the Super Bowl.
Find out more about Moms' Night Out
Please visit our Sponsors & Partners - they help make the show possible!
Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)
Check out VIVI Cap to protect your insulin from extreme temperatures
Learn more about AG1 from Athletic Greens
Drive research that matters through the T1D Exchange
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: info@diabetes-connections.com
This week, we get an update from Dexcom. Chief Operating Officer Jake Leach talks about their soon to be launched CGM for people with type 2. It's called Stelo and it's front of the FDA right now.
We also answer a lot of your questions about G6, G7, interoperability, connectivity and what's next.
Some information on Stelo: https://diatribe.org/new-dexcom-cgm-people-type-2-diabetes-not-using-insulin
Find out more about Moms' Night Out
Please visit our Sponsors & Partners - they help make the show possible!
Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)
Check out VIVI Cap to protect your insulin from extreme temperatures
Learn more about AG1 from Athletic Greens
Drive research that matters through the T1D Exchange
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: info@diabetes-connections.com
Episode summary (AI generated)
A new CGM product for people with type 2 diabetes.
Stacey Simms and Jake Leach discuss a new CGM product for people with type 2 diabetes, currently under FDA review.
Stello extends sensor wear to 15 days while maintaining accuracy and reliability for CGM users, regardless of insulin titration.
Stello aims to help people with diabetes understand how food impacts their glucose levels through a simple and user-friendly CGM device.
CGM for type 2 diabetes and payer coverage.
Jake Leach explains how the new CGM product will notify users of high glucose levels without alerting them to take insulin, providing valuable insights into food and diet impact on glucose levels.
Stacey Simms seeks more detail on the product and its potential for long-term use, expressing interest in education and training for users to fully understand and benefit from the technology.
Stacey Simms asks Jake Leach about the continuous use of CGMs, and Jake explains that the product is designed to be engaging and provide value continuously, with users learning and improving their diabetes management over time.
Jake also mentions that the company is working with payers to expand coverage for CGMs beyond Medicare, as it can be a challenge for people without insulin use.
CGM access, naming, and interoperability.
Stello is a cache pay product starting off affordable and competitive, with potential for reimbursement as evidence of benefits grows.
Jake Leach: Excited about new brand for Dexcom, with different design for new population, but still with expected performance reliability.
Jake Leach: G6 and G7 interoperability is a focus, with Omni pod integration and launch timing controlled by Dexcom.
G7 features and enhancements.
Jake Leach: Enhancements made to Bluetooth connectivity on G7 device, now available across channels and geographies.
Jake Leach discusses the company's focus on improving sensor reliability and user satisfaction through ongoing software development and user feedback.
The company prioritizes features based on user feedback and releases them in a timely manner, with a dedicated team working on the Apple Watch feature.
Dexcom's CGM technology and its potential for more widespread access.
Jake Leach and Stacey Simms discuss the evolution of G7, including its smaller size and reduced environmental footprint.
The company is working on a direct-to-watch submission and has validated alerts and alarms on the watch platform.
Dexcom aims to provide best CGM for users' pump systems, partnering with multiple companies globally.
Jake Leach is passionate about expanding access to CGM technology for people with diabetes worldwide.
This week, legal rights and diabetes have come a long way – but as the technology changes, so have some of the challenges. What happens when a school refuses to use CGM technology? I’m talking to two attorneys this week who have actionable advice and the law on their side. The Dept of Justice has already ruled on this in one state, in a decision that has nationwide impact.
Bonnie Roswig is an attorney with the small non profit Center for Children’s Advocacy which focuses on addressing legal needs of vulnerable children.
Jonathan Chappell lives with type 1 and is a private practice lawyer in Connecticut.
They recently filed an administrative complaint with DOJ in the Eastern district of VA, with more to come. They've also created a template for families, on their own to download, complete, and file on their own: Here's more information for parents
There's also a Facebook group that is following this issue: https://www.facebook.com/groups/followt1ds
This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Don't miss our Diabetes Summer Camp Webinar this week!
Find out more about Moms' Night Out
Please visit our Sponsors & Partners - they help make the show possible!
Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)
Check out VIVI Cap to protect your insulin from extreme temperatures
Learn more about AG1 from Athletic Greens
Drive research that matters through the T1D Exchange
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: info@diabetes-connections.com
It’s In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: a look at how weight loss might lower cancer risk in people with type 2, a new study that says BG spikes are good(?!), Modular Medical submits a new insulin pump the FDA, another look at COVID-19's effects on people with diabetes, a marathoner with type 1 heads to the last trial for this summer's Olympics, and more!
Find out more about Moms' Night Out
Please visit our Sponsors & Partners - they help make the show possible!
Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)
Check out VIVI Cap to protect your insulin from extreme temperatures
Learn more about AG1 from Athletic Greens
Drive research that matters through the T1D Exchange
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: info@diabetes-connections.com
Let's talk about diabetes camp! It’s probably still cold where you live, but now is the time to start planning. Your local camp may open for registration in the next couple of weeks.
My guest is the Dr. Gregory Fox, medical director of Camp Surefire in Rhode Island. He’s going to answer many common questions about sending your child away.. and he’ll talk about Camp Views – this is a system that lets staff monitor every single kid’s CGM in one place at all times.
This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Find out more about Moms' Night Out
Please visit our Sponsors & Partners - they help make the show possible!
Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)
Check out VIVI Cap to protect your insulin from extreme temperatures
Learn more about AG1 from Athletic Greens
Drive research that matters through the T1D Exchange
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: info@diabetes-connections.com
Have you heard about the rebel alliance of healthcare? That’s what my guest calls the patient-led movement to improve health & health care. Susannah Fox served as the Chief Technology Officer for the U.S. Department of Health & Human Services and she’s got a new book out called Rebel Health. If you’re thinking hey – that’s sounds like a lot of the diabetes community – oh yeah. You’re right and we talk about it.
This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Learn more about "Rebel Health" and order the book here: Rebel Health (mit.edu)
Find out more about Moms' Night Out
Please visit our Sponsors & Partners - they help make the show possible!
Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)
Check out VIVI Cap to protect your insulin from extreme temperatures
Learn more about AG1 from Athletic Greens
Drive research that matters through the T1D Exchange
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: info@diabetes-connections.com
It’s In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: Vertex pauses their stem cell transplantation trials after a patient death, spray insulin is tested, learning more about Dexcom's sensor for type 2, measuring A1C through menstrual blood and more!
Find out more about Moms' Night Out
Please visit our Sponsors & Partners - they help make the show possible!
Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)
Check out VIVI Cap to protect your insulin from extreme temperatures
Learn more about AG1 from Athletic Greens
Drive research that matters through the T1D Exchange
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: info@diabetes-connections.com
Episode transcript:
Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now.
XX
In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark
XX
Our top story this week…
XX
Vertex Pharmaceuticals, Inc. has paused a study of stem cell–derived, fully pancreatic islet cell replacement therapy (VX-880) following two patient deaths.
Neither death is related to the therapy itself - called VX-880 – according to the company. Vertex says they plan to share full data soon. In the study that was paused, 14 patients with type 1 received infusions of VX-880 and standard immunosuppression. After 90 days, 13 of the patients have an A1C under 7 without using exogenous insulin.
This was the study that made a big splash in the New York Times in late 2021 with the headline “A Cure for Type 1 Diabetes?” and featuring Brian Shelton among others. Shelton is one of the two patients who have died.
https://www.medscape.com/viewarticle/vertex-pauses-islet-cell-study-after-patient-deaths-2024a10000oe
XX
Early days but researchers in Norway are testing an insulin body spray.
Patients squirt the insulin directly on to their inner forearm, where skin tends to be thinner, allowing easier absorption. Within minutes, it gets absorbed into the bloodstream.
This joins other research on skin patches packed with micro-needles that punch tiny and reportedly painless holes in the skin to let insulin seep through.
The spray contains insulin and propylene carbonate, a chemical often used in cosmetic skin creams to help them penetrate the outer layers of the skin.
In this case, it’s hoped the chemical — attached to insulin in the spray droplets — will help the hormone seep as far as the tiny blood vessels that lie beneath the surface of the skin, where the hormone will then get absorbed into the bloodstream.
InsuLife, the Norwegian company developing the body spray, is setting up a trial involving 12 patients with type 1 diabetes to see how different doses of the spray compare with injected insulin in controlling blood-sugar levels. It is used just before a meal, like injected insulin.
The clinical trial was set up after a study involving five people found the spray reduced blood sugar levels by about 20 per cent after a meal.
https://www.dailymail.co.uk/health/article-12965203/insulin-spray-arm-diabetes-jab-Hope-sight-millions.html
XX
The FDA clears the Qvin’s Q-Pad™ A1c Test System which uses menstrual blood to get an A1C result.
The kit is intended for the collection of menstrual blood samples by individuals 18 years of age and older using the Q-Pad, a pad with an embedded blood collection strip (Q-Strip). Each kit includes 2 Q-Pads, a return sample container, and a stamped mailing pouch.
The FDA clearance was based on data from a clinical validation study that included 198 participants. Samples were collected using the Q-Pad Kit and were returned to the laboratory by mail. To provide the reference sample, a venous blood draw was performed on participants by a phlebotomist. An analysis of both samples demonstrated that the clinical performance of the Q-Pad test system in measuring HBA1c was equivalent to the traditional method of blood testing.
https://www.empr.com/home/news/fda-approved-q-pad-test-system-uses-menstrual-blood-to-measure-hba1c/
XX
Learning more about Dexcom’s upcoming CGM designed for people with type 2 who don’t use insulin. It’s to be called Stelo and they’ve submitted to the FDA with an eye on a late summer launch. I was at the announced last June – this is a system that will have very few alerts and alarms.. Stelo looks a lot like the G7 but will have different software and will last for about 15 days per sensor.
https://www.theverge.com/2024/1/11/24034098/dexcom-stelo-cgm-diabetes-health-tech-ces-2024
XX
Tandem Diabetes Care's t:slim X2 Insulin Pump Automated Insulin Delivery System is now the first to incorporate the Abbott FreeStyle Libre 2 Plus Sensor for users in the United States. The FreeStyle Libre 2 Plus sensor is a modified version of the FreeStyle Libre 2 sensor cleared in 2023 by the US Food & Drug Administration for use with automated insulin delivery (AID) systems.
The move follows Tandem's December announcement of integration with the recently available 10-day Dexcom G7 sensor.
https://www.medscape.com/viewarticle/tandem-insulin-pump-system-integrates-libre-sensor-2024a10000iq?form=fpf
XX
If you use Omnipod 5 with an Android, there’s a software update you need to do. The FDA has issued a Class one correction recall. due to a software error that occurs when the user enters a bolus amount less than 1 unit without putting a leading zero before the decimal point.
This recall is not a product removal and users should have already received an alert that won’t let them use the app until they do the software update.
XX
Embecta continues to move ahead with its insulin patch pump.. submitting a 510(k) premarket filing to the FDA for its proprietary insulin patch pump.
This is a disposable pump for people with type 2 diabetes. It also has a closed-loop version under development to follow. That version features an embedded algorithm that requires Embecta to run a clinical study.
Henry Anhalt, chief medical officer, says nine out of 10 people with diabetes live with type 2 diabetes. However, Anhalt says the majority of automated insulin delivery systems cater to those with type 1 diabetes. Embecta aims to offer more options and tools to the broader diabetes care community, he says.
https://www.drugdeliverybusiness.com/embecta-submits-insulin-patch-pump-fda/
XX
Update on insulin prices.. as a few prices changes went into affect at the beginning of the year. So, what took effect this month was that Sanofi followed suit with Eli Lilly and Novo Nordisk to implement this cap on insulin co-pays at $35 that took effect January 1.
And that comes after the provisions of the Inflation Reduction Act capped insulin for people on Medicare at $35. The Medicare cap is automatic and part of policy. For everyone with commercial insurance, the cap is voluntary from the companies. For those without government or private insurance, the picture is more complicated. If your insulin is still more than $35 per month, ask your pharmacist for coupons or check out getinsulin dot org.
https://www.pbs.org/newshour/show/new-law-caps-insulin-prices-for-some-with-diabetes-but-cost-remains-high-for-millions
XX
Commercial
XX
XX
Young adults who reported higher stress during their teenage years to adulthood were more likely to have high blood pressure, obesity and other cardiometabolic risk factors than their peers who reported less stress, according to new research published today in the Journal of the American Heart Association, an open access, peer-reviewed journal of the American Heart Association.
Cardiometabolic risk factors often occur together and are a significant cause of cardiovascular disease. These include obesity, Type 2 diabetes or prediabetes, high cholesterol and high blood pressure, researchers noted.
In 2020, cardiometabolic diseases, including cardiovascular diseases and Type 2 diabetes, were the most prevalent chronic health conditions and collectively accounted for nearly a quarter of all deaths in the U.S., according to the American Heart Association statistics. In 2023, the American Heart Association noted the strong connections among cardiovascular disease, kidney disease, Type 2 diabetes and obesity, and suggested redefining cardiovascular risk, prevention and management.
https://finance.yahoo.com/news/childhood-stress-linked-higher-risk-100000670.html
XX
Shout out to NBC News for a great story they did recently on LADA – featuring two women who have both been on this podcast. Dr. Phyllisa DeRoze and Mila Clark were both first misdiagnosed with type 2 before they got a correct diagnosis of LADA. I’ll link up the NBC story along with our chats with both women.. thanks to Mila for giving me a mention as one of the voices in the diabetes community who made her think was she had might not be type 2.. but could be LADA.
https://www.nbcnews.com/health/diabetes/diagnosed-type-2-diabetes-may-different-form-disease-rcna132571
XX
Join us again soon!
Why isn't blood glucose considered as, and monitored as, a vital sign? That's the question this week's guest is asking. Molly McElwee Malloy has big plans to change how hospitals and doctors are able to keep track of glucose.
You may recognize Molly. She's worked at Tandem Diabetes and kept us posted over the years about Control IQ and other advances there. She’s got a new job and this big new goal. As always with Molly, who lives with type 1, it’s a great conversation.
This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
our past episodes with Molly: https://diabetes-connections.com/?s=mcelwee
Find out more about Moms' Night Out
Please visit our Sponsors & Partners - they help make the show possible!
Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)
Check out VIVI Cap to protect your insulin from extreme temperatures
Learn more about AG1 from Athletic Greens
Drive research that matters through the T1D Exchange
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: info@diabetes-connections.com
Sernova is making progress developing a cell pouch system they hope will be a functional cure for type 1 diabetes. This week, we're talking to Sernova’s CEO Cynthia Pussinen for an update on their latest research, clinical trials and she answers your questions about everything from immunosuppressive drugs, how long people in these trials stay off insulin, and how to get into their trials.
This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Find out more about Moms' Night Out
Please visit our Sponsors & Partners - they help make the show possible!
Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)
Check out VIVI Cap to protect your insulin from extreme temperatures
Learn more about AG1 from Athletic Greens
Drive research that matters through the T1D Exchange
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: info@diabetes-connections.com
Happy New Year! It’s our first episode of 2024 so let’s talk about what this year could bring. I’m doing some predictions with the wonderful Gary Scheiner, MS, CDCES.
Gary is the founder of Integrated Diabetes Services and has been named Educator of the Year by the ADA. He’s the author of Think Like a Pancreas and has launched a podcast with the same name.
We’ll take a quick look back at 2023, find out what he’s most looking forward to in 2024 and what else we might expect in the months to come.
This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Find out more about Moms' Night Out
Please visit our Sponsors & Partners - they help make the show possible!
Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)
Check out VIVI Cap to protect your insulin from extreme temperatures
Learn more about AG1 from Athletic Greens
Drive research that matters through the T1D Exchange
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: info@diabetes-connections.com
It’s In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: a new study looks at food-as-medicine for type 2, another FDA warning about fake Ozempic, new research says gut markers may help predict who Tzield will work best for, JDRF partners with NFL and more...
Happy New Year - we'll see you in 2024!
Find out more about Moms' Night Out
Please visit our Sponsors & Partners - they help make the show possible!
Edgepark Medical Supplies
Check out VIVI Cap to protect your insulin from extreme temperatures
Learn more about AG1 from Athletic Greens
Drive research that matters through the T1D Exchange
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: info@diabetes-connections.com
Episode transcription:
Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now.
XX
In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark
XX
Our top story this week…
XX
You often hear people say food is medicine.. but an intensive program trying to show that’s the case did NOT improve glycemic control in adults with type 2 diabetes any better than usual care.
This was a randomized clinical trial. After 6 months, both groups had a similar drop in HbA1c -- 1.5 percentage points among program enrollees and 1.3 percentage points with usual care, with no significant differences in other metabolic lab values between the groups either, the researchers wrote in JAMA the food-as-medicine participants even gained some weight compared with the usual care group over 6 months (adjusted mean difference 1.95 kg, P=0.04).
"I was surprised by the findings because the program is so intensive," Doyle told MedPage Today. "The health system built brick-and-mortar clinics, staffed them with a dietitian, nurse, and community health worker, had weekly food pick-up for 10 meals per week for the entire family, and participants spend a year in the program."
Costing an estimated $2,000 annually per participant, the food-as-medicine program allowed participants to choose from a variety of vegetables, fruits, and entrees each week -- enough food for two meals a day, 5 days a week. They were also provided recipes and cooking instructions and met with dietitians to track goals. On the other hand, the control group was only provided usual care, a list of local food bank locations, and the option to join the program after 6 months.
The trial was conducted at two sites, one rural and one urban, in the mid-Atlantic region. It recruited 465 adults with type 2 diabetes who completed the study, all of whom started with an HbA1c of 8% or higher. All participants were also self-reported as food insecure. The average age was 54.6 years, 54.8% of participants were female, 81.3% were white, and most resided in the urban location. Of note, all participants also resided in the program's service area and were affiliated with the health system that ran it.
"One study should not be over-interpreted," said Doyle. "It is possible that such a program could work in other contexts, among patients less connected to a health system, or in other formats. The main alternative to providing healthy groceries and education is to provide pre-made 'medically tailored meals.'"
"I hope the study raises awareness of the potential for food-as-medicine programs to increase healthcare engagement and to push researchers and policymakers to generate more evidence on ways such programs can improve health."
It’s worth noting that there is very little study – much less clinical trial level study on this type of thing. The researchers say they hope it spurs more research to find methods that will have a large impact.
https://news.mit.edu/2023/food-medicine-diabetes-study-1227
https://www.medpagetoday.com/primarycare/dietnutrition/107998
XX
New information about moderate low carb diets for people with type 1.
The study published in The Lancet Regional Health - Europe is the largest of its kind to date. Participants were for different periods randomly assigned in a crossover manner to eat a traditional diet with 50% of the energy from carbohydrates, or a moderate low-carbohydrate diet with 30% of the energy from carbohydrates.
The 50 participants all had type 1 diabetes with elevated mean glucose, long-term blood sugar, and injection therapy with insulin or an insulin pump. Half were women, half men. The average age was 48 years.
Participants on a moderate low-carbohydrate diet were found to spend more time in what is known as the target range, the range within which people with type 1 diabetes should be in terms of glucose levels. The increase in time within the target range was an average of 68 minutes per day compared to the traditional diet, while the time with elevated values was reduced by 85 minutes per day.
The researchers saw no evidence of adverse effects.
https://www.news-medical.net/news/20231220/Moderate-low-carb-diet-safe-and-effective-for-adults-with-type-1-diabetes.aspx
XX
Researchers at Case Western Reserve University and University Hospitals have identified an enzyme that blocks insulin produced in the body—a discovery that could provide a new target to treat diabetes.
Their study, published Dec. 5 in the journal Cell, focuses on nitric oxide, a compound that dilates blood vessels, improves memory, fights infection and stimulates the release of hormones, among other functions. How nitric oxide performs these activities had long been a mystery.
The researchers discovered a novel “carrier” enzyme (called SNO-CoA-assisted nitrosylase, or SCAN) that attaches nitric oxide to proteins, including the receptor for insulin action.
Given the discovery, next steps could be to develop medications against the enzyme, he said.
https://thedaily.case.edu/new-cause-of-diabetes-discovered-offering-potential-target-for-new-classes-of-drugs-to-treat-the-disease/
XX
The Food and Drug Administration on Thursday warned consumers not to use counterfeit versions of Novo Nordisk's diabetes drug Ozempic that have been found in the country's drug supply chain.
The FDA said it will continue to investigate counterfeit Ozempic 1 milligram injections and has seized thousands of units, but flagged that some may still be available for purchase.
The agency said the needles from the seized injections are counterfeit and their sterility cannot be confirmed, which presents an additional risk of infection for patients.
Other confirmed counterfeit components from the seized products include the pen label and accompanying information about the healthcare professional and patient, as well as the carton. The FDA urged drug distributors, retail pharmacies, healthcare practitioners and patients to check the drug they have received and to not distribute, use or sell the units labeled with lot number NAR0074 and serial number 430834149057.
People who have Ozempic injections with the above lot number and serial number can report it directly to the FDA Office of Criminal Investigations.
https://www.nbcnews.com/health/health-news/fda-warns-ozempic-counterfeit-diabetes-weight-loss-rcna130871
XX
New research indicates that information in the gut may predict how well a person responds to Tzield. That’s the medication approved earlier this year to delay the onset of type 1. These findings reported in the journal Science Translational Medicine, casts a new spotlight on the immune system's relationship with the microbiome, revealing how gut microbes can shape the progression of type 1 diabetes. With this new knowledge in hand, clinicians may better pinpoint patients who are most likely to respond to teplizumab.
https://medicalxpress.com/news/2023-12-gut-microbes-patients-response-drug.html
XX
Experts are advocating for universal screening for type 1 diabetes. With the availability of Tzield and other medications on the horizon, there's a stronger push for screening earlier in life. At least 85% of people who are newly diagnosed do not have a family history of diabetes.
Testing for autoantibodies can be completed at home through the TrialNet clinical trial program, or at a doctor’s office or lab. For instance, JDRF’s T1Detect program provides at-home testing for $55, with lower-cost options for people in financial need.
The 2024 American Diabetes Association (ADA) Standards of Care recommend more intensive monitoring for the progression of preclinical type 1 diabetes. The Standards of Care also recommend using Tzield to delay the onset of diabetes in people at least 8 years old with stage 2 type 1 diabetes.
https://diatribe.org/type-1-diabetes-it%E2%80%99s-time-population-wide-screening
XX
Commercial
XX
https://www.healthline.com/health-news/the-years-biggest-medical-advancements-in-diabetes-treatment
XX
DRF, the leading global funder of type 1 diabetes (T1D) research, is recognizing the NFL stars who showcased their creativity and a remarkable show of support as part of the highly anticipated annual "My Cause My Cleats" (MCMC) campaign.
The My Cause My Cleats initiative allows NFL players to wear custom-painted cleats during selected games to raise awareness and funds for the charitable causes closest to their hearts. The unofficial start of the campaign begins on Giving Tuesday with unboxing day events showcasing the players' cleats and the stories behind them. It continues through weeks 13 and 14 of the season, culminating with the players donning their cleats on game day. After the games, some players donate their cleats to their chosen charities or the NFL auction, with all proceeds going toward their selected causes.
Type 1 Diabetes is a life-threatening autoimmune condition that affects people of all ages, regardless of family history or lifestyle choices. To live, people with T1D must carefully balance injecting or infusing insulin with their carbohydrate intake throughout the day and night. T1D impacts approximately 1.6 million people in the U.S. It is unpreventable, and there is currently no cure.
This year, JDRF is thankful for the support of several players who have T1D or are advocating for their loved ones with T1D, including Mark Andrews of the Baltimore Ravens, Orlando Brown, Jr. of the Cincinnati Bengals, Blake Ferguson of the Miami Dolphins, Collin Johnson of the Chicago Bears, Chad Muma of the Jacksonville Jaguars, Nate Peterman of the Chicago Bears, and Kevin Radar of the Tennessee Titans.
"The NFL players who support JDRF through the My Cause My Cleats exemplify the passion and determination at the heart of the type 1 diabetes community," said Kenya Felton, JDRF Director of PR and Celebrity Engagement. "They serve as inspirations for many adults and children affected by T1D, demonstrating that with an understanding of T1D, effective management, and a good support system, you can overcome the challenges of the disease. Their support helps to increase awareness and is significant in helping JDRF advance life-changing breakthroughs in T1D research and advocacy initiatives."
Since its inception in 2016, the MCMC campaign has provided a platform for many NFL players and affiliates to support JDRF's mission, including Beau Benzschawel, David Carr, Will Clarke, Keion Crossen, DeAndre Carter, Reid Ferguson, Jaedan Graham, Jarvis Jenkins, Collin Johnson, Henry Mondeaux, Jaelan Phillips, Adam Schefter, Brandon Wilds, and Jonah Williams.
XX
Join us again soon!